live In the news:
A stronger Ozempic is coming. What to know about CagriSema, Novo Nordisk's new weight loss drug - The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research - Weight loss drug industry injects wealth into Novo Nordisk home country - Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies - Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats - Novo Nordisk, Eli Lilly and the GLP-1 economy - 'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing - Sanders, Novo Nordisk CEO clash over Ozempic, Wegovy drug prices - Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad - Blame drug 'middlemen' for Ozempic and Wegovy prices, Novo Nordisk CEO tells Congress

Novo Nordisk

5 days ago
bookmarkSave

Key facts

Classified as: organization

Summary

Novo Nordisk is a company. It is located in Germany. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.

Business

  • Employees: get premium Premium to see estimate
  • Revenues: get premium Premium to see estimate

Stocks from Novo Nordisk

Explore more on business

Talking Points:

  • Novo Nordisk Pharma GmbH
  • Novo Nordisk ist ein weltweit führendes Unternehmen im Gesundheitswesen, das 1923 gegründet wurde und seinen Hauptsitz außerhalb von Kopenhagen, Dänemark, hat. Wir treiben Veränderungen voran mit dem Ziel, Diabetes und andere schwerwiegende chronische Krankheiten wie Adipositas und seltene Blut- und Stoffwechselkrankheiten zu besiegen.
  • Daily news about diabetes, obesity and other serious chronic diseases. We're global, but here in person for your questions and comments 💬 Community guide 👇
  • Driving change to defeat diabetes and other serious chronic diseases. Join us to learn more about our latest innovations | Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and ...
Learn more about talking points

In literature

There is no book written about Novo Nordisk in the database

Related

Connected or similar:

Details

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter

This content can be used under the CC BY 4.0 license